Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Philippe Moreau, Simon J. Harrison, Michele Cavo, Javier de La Rubia, Rakesh Popat, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Andrew Spencer, Michael O'Dwyer, Wan-Jen Hong, Muhammad Jalaluddin, Xiaoqing Yang, James Michael Pauff, Paulo Cesar Maciag, Jeremy A. Ross, Shaji Kumar
Institutions: Centre Hospitalier Universitaire de Nantes, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, Hospital Universitari i Politècnic La Fe, University College Hospital, University College London Hospitals NHS Foundation Trust, University College London, Asklepios Klinik Altona, Asklepios, Japanese Red Cross Medical Center, Seoul National University Hospital, Alfred Health, Monash University, Ollscoil na Gaillimhe – University of Galway, Genentech, AbbVie (United States), Vanderbilt University, Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3032218734